NCT04898101 - A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2016

Primary Completion Date

April 13, 2016

Study Completion Date

April 13, 2016

Conditions

Healthy Volunteers

Interventions

DRUG

Acalabrutinib

Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.

DRUG

Microtracer [14C]ACP-196

Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.

Trial Locations (1)

53704

Covance Clinical Research Unit, Inc., Madison